Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Optimal Neuroprotection of neu2000 in Ischemic Stroke With Endovascular reCanalizion (SONIC) (SONIC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02831088
Recruitment Status : Unknown
Verified December 2016 by GNT Pharma.
Recruitment status was:  Recruiting
First Posted : July 13, 2016
Last Update Posted : July 13, 2017
Sponsor:
Information provided by (Responsible Party):
GNT Pharma

Tracking Information
First Submitted Date  ICMJE July 3, 2016
First Posted Date  ICMJE July 13, 2016
Last Update Posted Date July 13, 2017
Study Start Date  ICMJE July 2016
Estimated Primary Completion Date December 30, 2018   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: July 11, 2017)
  • Proportional Ratios of study subjects with mRS 0-2 scores at 12 weeks after Neu2000KWL treatment [ Time Frame: 12weeks ]
  • Occurrence rate of cerebral hemorrhagic transformation occurring within 48 hours based on parenchymal hematoma (PH) criteria by ECASS (European Co-operative Acute Stroke Study)-I and II [ Time Frame: 12weeks ]
Original Primary Outcome Measures  ICMJE
 (submitted: July 8, 2016)
Ratios of study subjects with mRS 0-2 scores at 5 days, 4 and 12 weeks after first Neu2000KWL treatment vs baseline [ Time Frame: 5days, 4weeks, 12weeks ]
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: July 8, 2016)
  • Distribution changes of mRS scores at 1, 4 and 12 weeks vs baseline (shift analysis) [ Time Frame: 1week, 4weeks, 12weeks ]
  • Ratios of NIHSS 0-2 scores at 1, 4 and 12 weeks vs baseline [ Time Frame: 1week, 4weeks, 12weeks ]
  • Ratios of Barthel index >90 (≥ 95) at 1, 4 and 12 weeks vs baseline [ Time Frame: 1week, 4weeks, 12weeks ]
  • Occurrence rate of cerebral hemorrhagic transformation occurring within Day 4 or Day 5 (Day of the last treatment of the study drug) [ Time Frame: 4-5days ]
    based on parenchymal hematoma (PH) criteria by ECASS (European Co-operative Acute Stroke Study)-I and II
  • Occurrence rate of symptomatic intracranial hemorrhage (SICH) described and defined by this study protocol occurring within Day 4 or Day 5 (Day of the last treatment of the study drug) [ Time Frame: 4-5days ]
    It is defined as SICH of intracranial hemorrhage by brain imaging is confirmed and any one of the following conditions is accompanied: A. in case that NIHSS scores become worse 2 points or more B. in case that NIHSS scores become worse 1 point or more, accompanying decreased consciousness C. in case that neurological deficits persist 24 hours or more (and), D. in case of recurrence of stroke and progress deterioration, or in case that other medical causes are not related.
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Safety and Optimal Neuroprotection of neu2000 in Ischemic Stroke With Endovascular reCanalizion (SONIC)
Official Title  ICMJE A Phase II, Double-blind, Randomized, Placebo-controlled, Multi-center Study to Assess Efficacy and Safety of Neu2000KWL in Patients With Acute Ischemic Stroke Receiving Endovascular Therapy
Brief Summary Efficacy and safety of Neu2000, a multi-target drug designed to prevent both NMDA receptor-mediated excitotoxicity and free radical toxicity, will be investigated in acute ischemic stroke patients receiving endovascular treatment to remove clot within 8 hours following stroke onset. Neu2000KWL will be administered before endovascular treatment.
Detailed Description Neu2000 was designed as a multi-target neuroprotectant preventing both the NMDA receptor, a Ca2+-permeable glutamate receptor, and free radicals, two major routes of brain cell death in stroke. Neu2000 is a moderate NR2B-selective NMDA receptor antagonist and spin trapping molecule (=free radical scavenger or antioxidant). Therapeutic potential of Neu2000 has been well demonstrated in four animal models of stroke with better efficacy and therapeutic time windows than either NMDA receptor antagonist or anti-oxidant advanced to clinical trials. In human phase I studies of 165 healthy subjects conducted in the United States and China, Neu2000KWL showed promising safety profiles without any serious adverse events up to a single intravenous infusion of 6000 mg that is far beyond the therapeutic target dose determined in animal models of transient ischemic stroke. Very recently, acute endovascular recanalization therapy has been introduced as the new standard care of care in acute ischemic stroke. The present study is aimed to examine efficacy and safety of Neu2000KWL in acute ischemic stroke patients receiving endovascular thrombectomy within 8 hours of stroke onset.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Ischemic Stroke
Intervention  ICMJE
  • Drug: Neu2000KWL High-does group
    1st infusion of 750mg in patients receiving endovascular therapy within 8 hours following ischemic stroke onset followed by 9 consecutive infusions of 500 mg at intervals of 12 hours
    Other Name: Neu2000KWL is produced by GNT Pharma Pharmaceutical company
  • Drug: Neu2000KWL Low-does group
    1st infusion of 500mg in patients receiving endovascular therapy within 8 hours following ischemic stroke onset followed by 9 consecutive infusions of 250 mg at intervals of 12 hours
    Other Name: Neu2000KWL is produced by GNT Pharma Pharmaceutical company
  • Drug: Placebo
    1st infusion of the same volume of saline in patients receiving endovascular therapy within 8 hours following ischemic stroke onset followed by 9 consecutive infusions of same volume of saline at intervals of 12 hours
Study Arms  ICMJE
  • Experimental: Neu2000KWL High-dose group
    Intervention: Drug: Neu2000KWL High-does group
  • Experimental: Neu2000KWL Low-dose group
    Intervention: Drug: Neu2000KWL Low-does group
  • Placebo Comparator: Placebo
    Intervention: Drug: Placebo
Publications * Hong JM, Choi MH, Sohn SI, Hwang YH, Ahn SH, Lee YB, Shin DI, Chamorro Á, Choi DW; on the behalf of the SONIC investigators. Safety and Optimal Neuroprotection of neu2000 in acute Ischemic stroke with reCanalization: study protocol for a randomized, double-blinded, placebo-controlled, phase-II trial. Trials. 2018 Jul 13;19(1):375. doi: 10.1186/s13063-018-2746-9.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Unknown status
Estimated Enrollment  ICMJE
 (submitted: July 8, 2016)
210
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE December 30, 2018
Estimated Primary Completion Date December 30, 2018   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Adults ≥19 years
  2. Patients who were presented to hospitals after onset of brain ischemic symptoms from the base of last normal state and can start Endovascular therapy in accordance with standard practice guidelines within 8 hours after the symptom onset.
  3. NIHSS scores on screening time point (admission) ≥ 8 points
  4. Patients whose activity is possible without the help of others in the gen-eral condition one day before the ischemic stroke onset. and whose Barthel index scores exceed 90 points
  5. Patients whose brain CT and CT angiography imaging confirmed acute ischemic stroke and symptomatic intracranial occlusion at screening and whose occlusion site considered the cause of acute ischemic stroke meets the following conditions:

    ① Carotid T or L type occlusion

    ② M1 MCA

    ③ M1-MCA equivalent (two or more M2-MCAs) However, anterior temporal artery is not regarded M2

  6. Patients with ASPECTS on Brain CT without early imaging hyper-enhancement ≥ 6
  7. Patients who spontaneously submitted a written informed consent to participation on this clinical study

Exclusion Criteria:

  1. a medical history of hypersensitivity against aspirin (salicylates), sulfasalazine or (5-ASA) at screening.
  2. Patients who meets the exclusion criteria on imaging in intra-arterial re-canalization therapy ① CTA

    Patients whose imaging shows that the site of occlusion considered the cause of acute ischemic stroke meets the following conditions:

    A. MCA + PCA or MCA+ACA occlusion in Carotid T/L B. occlusion of a bilateral large artery C. simultaneous infiltration of anterior and posterior circulation

    ② absence of the collateral circulation corresponding to one of the followings: A. On CT angiography (MIP-CTA) imaging, absence or minimal collateral circulation at ≥50% of MCA territories, compared with pial filling of contralateral side of the lesion.

  3. Patients whose heart diseases corresponding to following conditions were confirmed at screening:

    ① Patients who were diagnosed with myocardial infarction within 6 months at screening

    ② Patients who had severe arrhythmia evoking clinical symptoms (respiratory difficulties, tachycardia etc.) within 6 months at screening.

    Patients whose ECG measured at the stable state at emergency room confirmed the following results:

    A. pulse rate < 50 or >120 beats per minute B. 2nd or 3rd degree AV block is confirmed. C. congenital or acquired QT syndrome is confirmed D. ventricular pre-excitation syndrome is confirmed

  4. Patients who were diagnosed with heart failure ≥ class II according to "heart failure classification by NYHA (New York Heart Association)" before screening.

    "heart failure classification by NYHA (New York Heart Association)" Class I: patients with no limitation of activities; they suffer no symptoms from ordinary activities.

    Class II: patients with slight, mild limitation of activity; they are comfortable with rest or with mild exertion.

    Class III: patients with marked limitation of activity; they are comfortable only at rest.

    Class IV: patients who should be at complete rest, confined to bed or chair; any physical activity brings on.

  5. Patients who have contraindication to contrast media for brain imaging
  6. Patients who are receiving renal replacement therapy such as dialysis, due to acute or chronic renal failure, nephropathy, etc. at screening.
  7. Patients who were diagnosed with cancer or received cancer therapy within 6 months at screening or have recurrent or transitional cancer
  8. Patients who show high body temperature of 38℃ or more or who need antibiotic therapy due to medical opinion of infectious diseases at screening.
  9. Patients who take pharmacotherapy due to liver diseases such as hepatitis, liver cirrhosis etc. at screening.
  10. Patients who are pregnant or lactating. However, in case of a woman of child-bearing potential, only patients whose non-pregnancy was confirmed can participate in this clinical study.
  11. Patients who participated in other clinical studies within past 3 months at the screening time as a base. However, in case of participation in an observatory study without medication, the patients can participate in this clinical study.
  12. Patients who were determined unsuitable for participation in this clinical study due to other reasons.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 19 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Korea, Republic of
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02831088
Other Study ID Numbers  ICMJE Neu2000KWL-P01
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE
Plan to Share IPD: Undecided
Responsible Party GNT Pharma
Study Sponsor  ICMJE GNT Pharma
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Ji Man Hong, MD, PhD Ajou University Medical Centre
PRS Account GNT Pharma
Verification Date December 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP